It consists of the inactivated recombinant M.hyocpPCV2 strain, named Nexhyon.
This innovative strain, expressing the PCV2 capsid protein in its cytoplasm, acts as the only active substance as a whole once inactivated.
Nexhyon represents the next generation of M.hyo vaccines based on recombinant biotechnology.